Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

TScan Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WALTHAM, MASS., JULY 29, 2026 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE FIRST PATIENT HAS BEEN INFUSED WITH TSC-101 IN THE PIVOTAL PHASE 3 ALLOHA-2 TRIAL (NCT07702578).

TSCAN THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 ALLOHA-2, A PIVOTAL TRIAL EVALUATING TSC-101 IN PATIENTS WITH HEME MALIGNANCIES

WALTHAM, MASS., JUNE 24, 2026 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE H.C. WAINWRIGHT 4TH ANNUAL CELL THERAPY VIRTUAL CONFERENCE ON TUESDAY, JUNE 30, 2026 AT 11:30 A.M. EASTERN TIME.

TSCAN THERAPEUTICS TO PARTICIPATE IN THE H.C. WAINWRIGHT 4TH ANNUAL CELL THERAPY VIRTUAL CONFERENCE

11 OF 14 PATIENTS DOSED HAD COMPLETE DONOR CHIMERISM WITHIN ~THREE WEEKS OF RECEIVING FIRST INFUSION OF TSC-101; AN ADDITIONAL TWO HAD IMPROVING CHIMERISM FOLLOWING TSC-101

TSCAN THERAPEUTICS ANNOUNCES POSITIVE INITIAL DATA FROM COHORT C OF ONGOING ALLOHA PHASE 1 STUDY EVALUATING TSC-101 IN PATIENTS WITH HEME MALIGNANCIES UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

SOUTH SAN FRANCISCO, CALIF. & WALTHAM, MASS.--(BUSINESS WIRE)--CELLARES, THE FIRST INTEGRATED DEVELOPMENT AND MANUFACTURING ORGANIZATION (IDMO), AND TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED AN AGREEMENT TO EVALUATE AUTOMATED CLINICAL MANUFACTURING OF TSC-101, TSCAN'S LEAD TCR-T THERAPY CANDIDATE FOR PATIENTS WIT.

CELLARES AND TSCAN THERAPEUTICS ANNOUNCE AGREEMENT TO EVALUATE AUTOMATED MANUFACTURING OF TSC-101 FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES

EARLY DATA ON PATIENTS TREATED IN COHORT C OF THE ALLOHA PHASE 1 HEME TRIAL EXPECTED IN THE SECOND QUARTER OF 2026 INITIATION OF PHASE 3 STUDY OF TSC-101 (ALLOHA-2  ) PLANNED FOR THE SECOND QUARTER OF 2026 INITIATION OF PHASE 1 STUDY OF TSC-102-A01 AND TSC-102-A03 TARGETING CD45 IN PATIENTS WITH HLA TYPES A*01:01 AND A*03:01 PLANNED FOR THE SECOND HALF OF 2026 CASH AND CASH EQUIVALENTS CONTINUE TO FUND OPERATIONS INTO THE SECOND HALF OF 2027 WALTHAM, MASS., MAY 06, 2026 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026, AND PROVIDED A CORPORATE UPDATE.

TSCAN THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

WALTHAM, MASS., APRIL 27, 2026 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THE ACCEPTANCE OF AN ABSTRACT FOR POSTER PRESENTATION AT THE UPCOMING AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT) 29 ANNUAL MEETING BEING HELD MAY 11  15 IN BOSTON, MA AS WELL AS VIRTUALLY.

TSCAN THERAPEUTICS ANNOUNCES UPCOMING PRESENTATION AT THE AMERICAN SOCIETY OF GENE AND CELL THERAPY 29TH ANNUAL MEETING

WALTHAM, MASS., APRIL 08, 2026 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 25THANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON WEDNESDAY, APRIL 15, 2026 AT 3:00 P.M. EASTERN TIME.

TSCAN THERAPEUTICS TO PARTICIPATE IN THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

PRESENTED POSITIVE UPDATED DATA FROM THE ALLOHA  PHASE 1 HEME TRIAL AT 67 TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION ANNOUNCED COMPLETION OF ENROLLMENT IN COHORT C OF PHASE 1 ALLOHA TRIAL; PATIENTS TO BE TREATED WITH COMMERCIAL-READY MANUFACTURING PROCESS ANNOUNCED EXPANSION OF HEME PROGRAM WITH FDA CLEARANCE OF TSC-102-A01 AND TSC-102-A03 TARGETING CD45, IN PATIENTS WITH HLA TYPES A*01:01 AND A*03:01 CASH AND CASH EQUIVALENTS CONTINUE TO FUND OPERATIONS INTO THE SECOND HALF OF 2027 WALTHAM, MASS., MARCH 04, 2026 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY REPORTED FINANCIAL RESULTS FOR THE THREE MONTHS AND FULL YEAR ENDED DECEMBER 31, 2025, AND PROVIDED BUSINESS UPDATES.

TSCAN THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

WALTHAM, MASS., FEB. 25, 2026 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A HYBRID PRESENTATION FOLLOWED BY AN ANALYST-LED Q&A SESSION AT THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE BEING HELD AT THE BOSTON MARRIOTT COPLEY PLACE IN BOSTON, MA ON WEDNESDAY, MARCH 4, 2026 AT 11:50 A.M. EASTERN TIME.

TSCAN THERAPEUTICS TO PARTICIPATE IN THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE

WALTHAM, MASS., DEC. 03, 2025 (GLOBE NEWSWIRE) -- TSCAN THERAPEUTICS, INC. (NASDAQ: TCRX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF T CELL RECEPTOR (TCR)-ENGINEERED T CELL (TCR-T) THERAPIES FOR THE TREATMENT OF PATIENTS WITH CANCER, TODAY ANNOUNCED THE COMPANY WILL HOST A VIRTUAL KEY OPINION LEADER (KOL) EVENT TO DISCUSS UPDATED DATA FROM THE ALLOHA PHASE 1 TRIAL BEING PRESENTED AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION AND THE FUTURE MARKET OPPORTUNITY FOR ITS HEME PROGRAM. THE VIRTUAL EVENT WILL TAKE PLACE ON MONDAY, DECEMBER 8, AT 8:00 A.M. ET.

TScan Therapeutics, Inc.

TCRX

Price

Financial Reports

No items found.

Press Releases

TScan Therapeutics, Inc.

TCRX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TCRX